CD4 and pneumocystosis: The current recommendation for first-line prophylaxis against PCP is trimethoprim-sulfamethoxazole (TMP-SMX) and is used in high-risk patients throughout the time of treatment-induced immunosuppression or until the CD4 count increases to above 200 cells/μL [2,3,5,12,13].